Jul 2026· Breast Cancer Research· Vol 28· 0 citations· 46 references
Medicine
TL;DR
Findings reveal that EMT is associated with immune cell recruitment and function in a graded manner, providing a rationale for integrating EMT phenotyping into therapeutic strategies to overcome immune resistance in breast cancer.
Abstract
Epithelial-mesenchymal transition (EMT) is a dynamic process that contributes to breast cancer progression, metastasis, and therapy resistance. EMT also influences the tumor immune microenvironment, shaping immune cell infiltration and function. Although the immunological features of fully epithelial or fully mesenchymal tumor states have been characterized, the immune landscape associated with intermediate or partial EMT states remains poorly understood. To examine the relationship between EMT progression and immune cell composition and function, we established five single-cell–derived clonal populations from the triple-negative 4T1 mouse mammary tumor cell line, representing a spectrum of EMT phenotypes, and analyzed tumors derived from these clones using single-cell RNA sequencing. Tumors derived from these clones retained their relative EMT states in vivo, and EMT progression was associated with a graded reduction in tumor immunogenicity, accompanied by alterations in immune cell composition and function. Along the EMT spectrum, tumor cells exhibited progressive downregulation of major histocompatibility complex (MHC) class I and II gene expression, along with decreased infiltration of cytotoxic CD8+ T cells and reduced expression of key effector and trafficking genes (Gzmb, Ccr5, Cxcr6). B cell composition also shifted, with decreased frequencies of IgG1-producing plasma cells and an enrichment of regulatory-like B cells. Natural killer (NK) cells similarly demonstrated progressive functional suppression, marked by reduced expression of cytotoxic molecules and the downregulation of specific effector pathways. These findings reveal that EMT is associated with immune cell recruitment and function in a graded manner, providing a rationale for integrating EMT phenotyping into therapeutic strategies to overcome immune resistance in breast cancer.
Findings indicate that a pro-tumorigenic microenvironment associated with disease progression in bladder cancer exists within peri-tumoral TLS and potentially a factor underlying contrasting therapeutic associations potentially driven by live microbial versus targeted immunomodulatory therapy in NMIBC and MIBC.
Findings delineate context-dependent transcriptional interactions between ICP and EMT pathways in ESCC and highlight the complexity of the tumor immune microenvironment beyond single-parameter biomarkers such as TMB.
M. Montazer, Fatemeh Fardi Golyan, Majedeh Ramian Yarasmi et al.· Egyptian Journal of Medical...· 0 citations
These findings identify CELSR2 as a previously unknown regulator of epithelial-mesenchymal plasticity and reveal that heterogeneous CELSR2 expression shapes spatially and functionally distinct tumor cell populations, thereby contributing to intratumoral heterogeneity in TNBC.
Julia Koren, Nour-Islem Yanis Saidani, Abdessamad Elkaoutari et al.· bioRxiv· 0 citations
Unraveling the intricate mechanisms of EMT activation in cancer will contribute to the advancement of personalized medicine and the design of more effective treatments against metastatic disease and pave the way for advancements in personalized medicine and improved treatment strategies for patients affected by EMT-rel...
Vafa Meftahpour, T. C. Dakal, Jarek Maciaczyk et al.· Signal Transduction and Targ...· 0 citations
Targeting the mechanisms regulating Treg recruitment, stability, or suppressive function may represent a promising strategy to enhance the efficacy of immunotherapies including Bacillus Calmette–Guérin therapy.
Yusuke Fukiage, Nodoka Okubo, M. Taga et al.· Frontiers in Molecular Biosc...· 0 citations
Multi-omics profiling of ESCC patients receiving neoadjuvant therapy is presented and a response-associated CX3CR1⁺CD8⁺ cytotoxic effector state is identified that may inform neoadjuvant ICI-based therapy in ESCC.
Ya-Hui Zhao, Ruixiang Zhang, Yang Li et al.· Nature Communications· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.